5-methoxy-2-(1-(3,4,5-trimethoxyphenyl)-1H-1,2,3-triazol-5-yl)phenol | 1363603-24-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-methoxy-2-(1-(3,4,5-trimethoxyphenyl)-1H-1,2,3-triazol-5-yl)phenol
• 英文别名: 5-Methoxy-2-[3-(3,4,5-trimethoxyphenyl)triazol-4-yl]phenol；5-methoxy-2-[3-(3,4,5-trimethoxyphenyl)triazol-4-yl]phenol
• CAS: 1363603-24-0
• 化学式: C₁₈H₁₉N₃O₅
• 分子量: 357.366
• InChiKey: YOMVTNUTNPBUEI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  26
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  87.9
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  2-(tert-butyldimethylsilyloxy)-4-methoxybenzaldehyde 在 四丁基氟化铵 、 乙基氯化镁 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 7.5h， 生成 5-methoxy-2-(1-(3,4,5-trimethoxyphenyl)-1H-1,2,3-triazol-5-yl)phenol
  参考文献：
  名称：

  Increased endothelial cell selectivity of triazole-bridged dihalogenated A-ring analogues of combretastatin A–1

  摘要：

  The antiproliferative activity on ovarian cancer (SK-OV-3) cells of a series of triazole-bridged combretastatin analogues (37, 38, 40-43) containing dihalogenation of the A-ring is reported, and compared with their trimethoxy analogues (5, 15, 39). It was found that dihalogenation with either bromine or iodine was a tolerated modification when compared to the parent compound combretastatin (CA-4, 1) and had less effect than B-ring modification on potency. These compounds exhibited G(2)/M arrest, and maintained antitubulin activity. Further assays on human umbilical vein endothelial cells (HUVECs) demonstrated the potential antivascular effects of these triazoles. Of particular note was a 3,5-diiodo-4-methoxyaryl triazole (43) which had promising 7-fold selectivity for HUVECs over ovarian cancer cells. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.01.010

文献信息

• Compounds for the treatment of proliferative disorders
  申请人：Demko Zachary

  公开号：US20070238699A1

  公开（公告）日：2007-10-11

  The invention relates to compounds of structural formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, and prodrug thereof, wherein R a , R b , and R 2 are defined herein. These compounds inhibit tubulin polymerization and/or target vasculature and are useful for treating proliferative disorders, such as cancer.

  本发明涉及结构式（I）的化合物：或其药学上可接受的盐，溶剂化物，包合物和前药，其中Ra，Rb和R2在此定义。这些化合物抑制微管聚合和/或靶向血管系统，并用于治疗增殖性疾病，如癌症。
• Compounds for the treatment of angiogenesis
  申请人：Wu Yaming

  公开号：US20100093670A1

  公开（公告）日：2010-04-15

  The invention relates to isoxazole, isothiazole, and triazole compounds that are useful for treating or inhibiting angiogenesis.

  该发明涉及对治疗或抑制血管生成有用的异唑、异硫唑和三唑化合物。
• COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS
  申请人：Demko Zachary

  公开号：US20100279410A1

  公开（公告）日：2010-11-04

  The invention relates to compounds of structural formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, and prodrug thereof, wherein R a , R b , and R 2 are defined herein. These compounds inhibit tubulin polymerization and/or target vasculature and are useful for treating proliferative disorders, such as cancer.

  本发明涉及结构式（I）的化合物：或其药学上可接受的盐，溶剂化合物，笼合物和前药，其中Ra，Rb和R2在此定义。这些化合物抑制微管聚合和/或靶向血管系统，可用于治疗增殖性疾病，如癌症。
• 1, 2, 3 -TRIAZOLES INHIBITORS OF TUBULIN POLYMERIZATION FOR THE TREATMENT OF POLIFERATIVE DISORDERS
  申请人：Synta Pharmaceuticals Corporation

  公开号：EP1919881A1

  公开（公告）日：2008-05-14
• COMPOUNDS FOR THE TREATMENT OF ANGIOGENESIS
  申请人：Synta Pharmaceuticals Corporation

  公开号：EP2059250A2

  公开（公告）日：2009-05-20